You Have No Risk Factors. That's Not the Same as No Risk.

Yes, blood pressure monitoring still matters if your pregnancy is healthy. Having no risk factors is not the same as having no risk. Being classified low-risk means no flaggable marker was found, not that the risk is zero. Ask your care team if blood pressure checks at home belong in your care.

A healthy pregnancy with no risk factors does not mean blood pressure monitoring is unnecessary. Preeclampsia, a pregnancy-specific condition where blood pressure rises dangerously and can damage organs, develops in roughly 1 in 19 first-time pregnancies in the system classified as low-risk (North et al., 2011). If your midwife hasn't flagged anything, and your appointments have been unremarkable, the natural conclusion is that blood pressure monitoring is someone else's concern: something the care team escalates when there's an actual reason to look. That assumption is coherent. It is also answering the wrong question.

The question "am I high-risk?" is about whether a recognizable marker is present. The question "does monitoring belong in my prenatal care?" is about whether blood pressure can change significantly in a pregnancy with no prior markers, and whether you would know before it mattered. These are different questions, and the answer to the first tells you nothing reliable about the second.

Monitoring has been positioned, consistently, as a tool for pregnancies already under heightened clinical attention. The result is that women in healthy, first-time pregnancies receive the implicit message that their status is sufficient evidence they don't need it. That message is understandable. It didn't come from nowhere. The category's framing has consistently pointed in exactly that direction, and that's worth understanding before accepting it.

Why the 'High-Risk Only' Message Feels True

The 'high-risk only' framing feels true because clinical language and risk-factor checklists consistently imply that unflagged pregnancies don't need monitoring. But that message reflects the system's sorting logic, not a clinical assessment of actual risk.

The information environment around blood pressure in pregnancy has a consistent shape. Most content about it (apps, pregnancy guides, the conversations that happen at routine appointments) introduces monitoring alongside a list of factors that trigger it: chronic hypertension, kidney disease, diabetes, a BMI above a threshold, a family history that points in a specific direction. The implied logic is sorting. These factors identify the women who need extra attention; the rest are implicitly sorted out.

Clinical language reinforces this. The phrase "high-risk pregnancy" does real work: it names a category, and by naming it, it implies an equal and opposite category of pregnancies that are not high-risk. When a provider describes your pregnancy as low-risk, healthy, or unremarkable, the natural interpretation is that monitoring belongs to the other group. The absence of a flag reads as an answer.

This framing has a real basis, not just an unfortunate turn of phrase. Risk stratification is a rational way to allocate limited clinical attention, and identifying factors that predict complications is genuinely useful medical practice. The language that emerged from it (risk factors, flagged, high-risk) describes a real system designed to concentrate monitoring where it is most visibly needed.

The practical message this produces is: monitoring is something that gets recommended when there is a reason to recommend it. If your provider hasn't mentioned it, the sensible reading is that there isn't a reason. You internalized a system's logic, not a misconception.

But a message being coherent within a system's logic is not the same as that message being complete. The sorting system directs attention toward the signals it can detect. The evidence about first-time, healthy pregnancies concerns what happens in the space the system wasn't built to see.

What a Study of 3,500 'Healthy' First-Time Pregnancies Found

The SCOPE study (Screening for Pregnancy Endpoints) was designed to examine exactly the pregnancies assumed to be exempt from monitoring. Researchers enrolled 3,572 healthy nulliparous women, each carrying a singleton pregnancy, at five centers across New Zealand, Australia, the United Kingdom, and Ireland (North et al., 2011). Nulliparous means no prior births. Healthy means none of the major pre-existing conditions, like chronic hypertension, diabetes, or kidney disease, that would have raised a flag at intake. These were the pregnancies the sorting system was built to pass through.

Of the 3,529 women for whom outcome data were available, 186 developed preeclampsia: 5.3 percent, roughly 1 in 19 (North et al., 2011). The finding was not drawn from a high-risk cohort. It came from the population assumed lowest-risk by the sorting system: first-time, healthy, no prior pregnancy history.

The same study built a clinical risk prediction model for this population and tested how well it could distinguish, in advance, between women who would and would not develop preeclampsia. Under internal validation, the model achieved an area under the receiver operating characteristic curve (AUC) of 0.71 (North et al., 2011). A score of 0.5 is a coin flip. A score of 1.0 is perfect discrimination. At 0.71, the model performed better than chance, but a score in this range still means a meaningful share of eventual cases fall outside what the model would flag as elevated risk. "Moderate discrimination" is the clinical description. In practical terms, it means a meaningful portion of the women who would go on to develop preeclampsia were not identifiable by the model beforehand.

Part of the reason for that gap is structural. The single strongest risk factor in clinical prediction of preeclampsia, across the broader evidence base, is a prior history of the condition. But that factor cannot be applied to nulliparous women, because nulliparous women have no prior pregnancies to reference (Bartsch et al., 2016). The group with the highest incidence of preeclampsia is simultaneously the group for whom the most predictive single risk factor is, by definition, unavailable.

Research suggests that a substantial share of preeclampsia cases occur in exactly this population: low-risk, first-time pregnancies with no traditional risk factors present (see References).

The SCOPE finding applies to a specific population: healthy, nulliparous, singleton pregnancies. The broader claim that monitoring matters in every pregnancy is a position built on this evidence, not a finding the study itself establishes. What the evidence does establish is this: if the tools available to predict preeclampsia in the highest-incidence group achieve only moderate discrimination, and that group cannot be flagged by the most predictive available factor, then "am I high-risk?" was never the question that could reliably answer whether monitoring belongs in your care.

Being Unflagged Doesn't Mean Safe to Skip — Here's What to Ask Your Provider

I call this the Doorman Fallacy. A doorman's job is to flag who needs extra scrutiny at the entrance; someone who walks past unchallenged hasn't been certified safe. They simply weren't stopped. Screening for preeclampsia works the same way. Being classified "not high-risk" means the tool didn't find a flaggable marker. It doesn't mean the risk is absent. For first-time mothers, that absence has a structural cause: the single strongest predictor of preeclampsia, prior history of the condition, cannot, by definition, apply to a first pregnancy.

I'd argue the question was never "Am I high-risk?" It was always whether the tools available could flag you at all. The right question is: "Does routine blood pressure monitoring belong in my prenatal care?" A systematic review of 92 studies covering more than 25 million pregnancies found that prior preeclampsia carries a pooled relative risk of 8.4 for preeclampsia in a subsequent pregnancy, the strongest predictor in clinical risk assessment (Bartsch et al., BMJ, 2016). First-time mothers have no prior pregnancy to draw that flag from. The most powerful signal the screening system possesses cannot be raised for the population it concerns most.

The scale of that gap becomes concrete in a specialist referral framework derived from the SCOPE model. A protocol built on a 15% probability threshold, or an abnormal uterine artery Doppler alongside a single risk factor, would refer roughly 9% of nulliparous women for specialist opinion; of those referred, 21% go on to develop preeclampsia (North et al., 2011). This is a research model, not a critique of clinical guidelines. But the numbers make the structural reality visible: the remaining 91% of the highest-incidence group proceeds through standard prenatal care, with blood pressure checked at routine visits but no escalated or home monitoring layered on top, not because their risk was assessed and found low, but because the tools available found no flaggable marker.

Asking whether more frequent monitoring belongs in your own care plan is a reasonable response to that gap, not paranoia.

When Should You Start Monitoring Blood Pressure in Pregnancy?

Blood pressure monitoring can start early in pregnancy, with a baseline reading that shows what's normal for you. That early reading makes it easier to tell if a later one is a change for you. Ask your care team if monitoring makes sense for your pregnancy.

If your provider hasn't brought up blood pressure monitoring, that doesn't mean you shouldn't have it. It may just mean the question hasn't come up yet. Asking is how it comes up. A monitoring-aware care plan has three elements: a baseline reading early in pregnancy to establish what's normal for you, a protocol for ongoing measurement, and a way to share readings with your care team between appointments. The baseline is what an assumption-driven approach usually misses: without an early reference point, it's harder to tell whether a later reading reflects your own pattern shifting, not just whether it crosses a general threshold.

ACOG endorses home blood pressure monitoring throughout pregnancy for women already diagnosed with hypertension, without specifying exactly how it should be performed (ACOG, 2020) — that guidance is specific to hypertension, not a blanket recommendation for healthy, unflagged pregnancies. The case for asking about it here isn't that a guideline requires it for you; it's the detection gap SCOPE describes above. That's precisely why the conversation with your provider matters: whether monitoring makes sense for your specific pregnancy, and if so, device, frequency, and how you'll share readings, are worked out between you, not resolved by a guideline document.

Three questions worth bringing to your next appointment:

"Should routine blood pressure monitoring be part of my prenatal care plan, given this is my first pregnancy?"

"What would my monitoring protocol look like? How often, and how would I share readings with you?"

"What would you want me to do if I get a reading that concerns me?" This last question is where your personal threshold lives. Your provider answers it; you don't look it up in an article.

Asking these questions isn't a sign something is wrong, and it isn't overcorrecting for anxiety. It reflects what the evidence about this population actually shows: risk-factor screening alone leaves a real gap for first-time mothers, and raising monitoring is a reasonable way to ask whether that gap applies to you, not a claim that monitoring itself is proven to catch more cases early. Home blood pressure monitoring supports clinical care. It doesn't replace it. Your role is to make sure the data exists, so your provider has more to work with than a single appointment can show.

A reading at or above 160/110, or a headache that won't go away, vision changes, or pain under your ribs, call your care team that day, no matter what your risk-factor screen said or how routine your pregnancy has been.

Want the short version of this argument? "Can You Get Preeclampsia With No Risk Factors?" answers the direct question in under two minutes. Link to be added when both pieces are live.

Frequently Asked Questions

Do I need to monitor my blood pressure if my pregnancy is considered low-risk?

Yes. A large study of over 3,500 healthy, first-time pregnancies (the SCOPE study) found that about 1 in 19 developed preeclampsia, even though none had the risk factors that usually trigger extra attention. Being classified low-risk means no flaggable marker was found, not that the risk is zero.

Can preeclampsia happen with no risk factors at all?

Yes. The single strongest known predictor of preeclampsia is a prior history of the condition, which is unavailable for anyone in a first pregnancy by definition. That's a structural gap in risk-factor screening, not a rare exception, and it's part of why the SCOPE study found meaningful preeclampsia rates even in a population with no traditional risk factors present.

Does ACOG recommend home blood pressure monitoring for a healthy pregnancy?

ACOG's home-monitoring endorsement is specific to women already diagnosed with hypertension, not a blanket recommendation for every healthy pregnancy. The case for asking about monitoring in a low-risk, first-time pregnancy rests on the detection gap SCOPE describes, not a guideline requirement, which is why it's worth raising directly with your provider.

References

1. Kenny LC, Black MA, Poston L, et al. Early Pregnancy Prediction of Preeclampsia in Nulliparous Women, Combining Clinical Risk and Biomarkers: The Screening for Pregnancy Endpoints (SCOPE) International Cohort Study. Hypertension. 2014;64(3):644-652. https://pubmed.ncbi.nlm.nih.gov/25122928/
2. American College of Obstetricians and Gynecologists (ACOG). Gestational Hypertension and Preeclampsia. ACOG Practice Bulletin No. 222 (Interim Update). Obstetrics & Gynecology. 2020;135(6):e237-e260. https://pubmed.ncbi.nlm.nih.gov/32443079/
3. Bartsch E, Medcalf KE, Park AL, Ray JG; High Risk of Pre-eclampsia Identification Group. Clinical Risk Factors for Pre-eclampsia Determined in Early Pregnancy: Systematic Review and Meta-analysis of Large Cohort Studies. BMJ. 2016;353:i1753. https://pubmed.ncbi.nlm.nih.gov/27094586/
4. North RA, McCowan LM, Dekker GA, et al. Clinical Risk Prediction for Pre-eclampsia in Nulliparous Women: Development of Model in International Prospective Cohort. BMJ. 2011;342:d1875. https://pubmed.ncbi.nlm.nih.gov/21474517/